Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neurilemmoma × tanezumab × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Schwannomatosis 1 Pain 1 Neurilemmoma 1 Neoplasm Metastasis 1 Hereditary Sensory and Autonomic Neuropathies 1

Interventions

tanezumab 1 siltuximab 1 erenumab 1 antineoplaston AS 2-1 1 antineoplaston A10 1 Saline Solution 1 Mn-PyC3A 1 Lapatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04163419 2024-03-13

Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis

Massachusetts General Hospital

Phase 2 Active not recruiting

Schwannomatosis, Neurilemmoma, Hereditary Sensory and Autonomic Neuropathies, Pain

Data powered by HemOnc (CC BY 4.0) Colophon ⚡